韩国耐多药/利福平结核病患者在治疗期间死亡的时间和预测因素。

IF 2.2 4区 医学 Q2 MEDICINE, GENERAL & INTERNAL
Korean Journal of Internal Medicine Pub Date : 2024-07-01 Epub Date: 2024-06-24 DOI:10.3904/kjim.2024.029
Eunjeong Son, Hongjo Choi, Jeongha Mok, Young Ae Kang, Dawoon Jeong, Doosoo Jeon
{"title":"韩国耐多药/利福平结核病患者在治疗期间死亡的时间和预测因素。","authors":"Eunjeong Son, Hongjo Choi, Jeongha Mok, Young Ae Kang, Dawoon Jeong, Doosoo Jeon","doi":"10.3904/kjim.2024.029","DOIUrl":null,"url":null,"abstract":"<p><strong>Background/aims: </strong>This study aimed to investigate the timing and predictors of death during treatment among patients with multidrug/rifampin-resistant tuberculosis (MDR/RR-TB) in South Korea.</p><p><strong>Methods: </strong>This was a retrospective cohort study that included MDR/RR-TB cases notified between 2011 and 2017 in South Korea.</p><p><strong>Results: </strong>Among 7,226 MDR/RR-TB cases, 699 (9.7%) died at a median of 167 days (IQR 51-358 d) from the initiation of MDR-TB treatment. The cumulative proportion of all-cause death was 35.5% at 90 days and 52.8% at 180 days from treatment initiation. TB-related deaths occurred at a median of 133 days (IQR 32-366 d), which was significantly earlier than the median of 184 days (IQR 68-356 d) for non-TB-related deaths (p = 0.002). In a multivariate analysis, older age was the factor most strongly associated with death, with those aged ≥ 75 years being 68 times more likely to die (aHR 68.11, 95% CI 21.75-213.26), compared those aged ≤ 24 years. In addition, male sex, comorbidities (cancer, human immunodeficiency virus, and end stage renal disease), the lowest household income class, and TB-specific factors (previous history of TB treatment, smear positivity, and fluoroquinolone resistance) were identified as independent predictors of all-cause death.</p><p><strong>Conclusion: </strong>This nationwide study highlights increased deaths during the intensive phase and identifies high-risk groups including older people and those with comorbidities or socioeconomic vulnerabilities. An integrated and comprehensive strategy is required to reduce mortality in patients with MDR/RR-TB, particularly focusing on the early stages of treatment and target populations.</p>","PeriodicalId":48785,"journal":{"name":"Korean Journal of Internal Medicine","volume":" ","pages":"640-649"},"PeriodicalIF":2.2000,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11236803/pdf/","citationCount":"0","resultStr":"{\"title\":\"Timing and predictors of death during treatment in patients with multidrug/rifampin-resistant tuberculosis in South Korea.\",\"authors\":\"Eunjeong Son, Hongjo Choi, Jeongha Mok, Young Ae Kang, Dawoon Jeong, Doosoo Jeon\",\"doi\":\"10.3904/kjim.2024.029\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background/aims: </strong>This study aimed to investigate the timing and predictors of death during treatment among patients with multidrug/rifampin-resistant tuberculosis (MDR/RR-TB) in South Korea.</p><p><strong>Methods: </strong>This was a retrospective cohort study that included MDR/RR-TB cases notified between 2011 and 2017 in South Korea.</p><p><strong>Results: </strong>Among 7,226 MDR/RR-TB cases, 699 (9.7%) died at a median of 167 days (IQR 51-358 d) from the initiation of MDR-TB treatment. The cumulative proportion of all-cause death was 35.5% at 90 days and 52.8% at 180 days from treatment initiation. TB-related deaths occurred at a median of 133 days (IQR 32-366 d), which was significantly earlier than the median of 184 days (IQR 68-356 d) for non-TB-related deaths (p = 0.002). In a multivariate analysis, older age was the factor most strongly associated with death, with those aged ≥ 75 years being 68 times more likely to die (aHR 68.11, 95% CI 21.75-213.26), compared those aged ≤ 24 years. In addition, male sex, comorbidities (cancer, human immunodeficiency virus, and end stage renal disease), the lowest household income class, and TB-specific factors (previous history of TB treatment, smear positivity, and fluoroquinolone resistance) were identified as independent predictors of all-cause death.</p><p><strong>Conclusion: </strong>This nationwide study highlights increased deaths during the intensive phase and identifies high-risk groups including older people and those with comorbidities or socioeconomic vulnerabilities. An integrated and comprehensive strategy is required to reduce mortality in patients with MDR/RR-TB, particularly focusing on the early stages of treatment and target populations.</p>\",\"PeriodicalId\":48785,\"journal\":{\"name\":\"Korean Journal of Internal Medicine\",\"volume\":\" \",\"pages\":\"640-649\"},\"PeriodicalIF\":2.2000,\"publicationDate\":\"2024-07-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11236803/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Korean Journal of Internal Medicine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.3904/kjim.2024.029\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/6/24 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q2\",\"JCRName\":\"MEDICINE, GENERAL & INTERNAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Korean Journal of Internal Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3904/kjim.2024.029","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/6/24 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0

摘要

背景/目的本研究旨在调查韩国耐多药/利福平肺结核(MDR/RR-TB)患者在治疗期间死亡的时间和预测因素:这是一项回顾性队列研究,纳入了2011年至2017年间韩国通报的MDR/RR-TB病例:在7226例MDR/RR-TB病例中,有699例(9.7%)在开始接受MDR-TB治疗后的167天(IQR为51-358天)内死亡。在开始治疗 90 天和 180 天时,全因死亡的累计比例分别为 35.5%和 52.8%。肺结核相关死亡的中位数为 133 天(IQR 32-366 d),明显早于非肺结核相关死亡的中位数 184 天(IQR 68-356 d)(p = 0.002)。在多变量分析中,年龄较大是与死亡关系最密切的因素,与年龄≤24岁的人相比,年龄≥75岁的人死亡的可能性要高出68倍(aHR 68.11,95% CI 21.75-213.26)。此外,男性性别、合并症(癌症、人类免疫缺陷病毒和终末期肾病)、最低家庭收入等级和结核病特异性因素(既往结核病治疗史、涂片阳性和氟喹诺酮耐药性)被确定为全因死亡的独立预测因素:这项全国性研究强调了强化阶段死亡人数的增加,并确定了包括老年人、合并症患者或社会经济弱势群体在内的高危人群。需要采取综合全面的策略来降低耐多药/耐药结核病患者的死亡率,尤其要关注治疗的早期阶段和目标人群。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Timing and predictors of death during treatment in patients with multidrug/rifampin-resistant tuberculosis in South Korea.

Background/aims: This study aimed to investigate the timing and predictors of death during treatment among patients with multidrug/rifampin-resistant tuberculosis (MDR/RR-TB) in South Korea.

Methods: This was a retrospective cohort study that included MDR/RR-TB cases notified between 2011 and 2017 in South Korea.

Results: Among 7,226 MDR/RR-TB cases, 699 (9.7%) died at a median of 167 days (IQR 51-358 d) from the initiation of MDR-TB treatment. The cumulative proportion of all-cause death was 35.5% at 90 days and 52.8% at 180 days from treatment initiation. TB-related deaths occurred at a median of 133 days (IQR 32-366 d), which was significantly earlier than the median of 184 days (IQR 68-356 d) for non-TB-related deaths (p = 0.002). In a multivariate analysis, older age was the factor most strongly associated with death, with those aged ≥ 75 years being 68 times more likely to die (aHR 68.11, 95% CI 21.75-213.26), compared those aged ≤ 24 years. In addition, male sex, comorbidities (cancer, human immunodeficiency virus, and end stage renal disease), the lowest household income class, and TB-specific factors (previous history of TB treatment, smear positivity, and fluoroquinolone resistance) were identified as independent predictors of all-cause death.

Conclusion: This nationwide study highlights increased deaths during the intensive phase and identifies high-risk groups including older people and those with comorbidities or socioeconomic vulnerabilities. An integrated and comprehensive strategy is required to reduce mortality in patients with MDR/RR-TB, particularly focusing on the early stages of treatment and target populations.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Korean Journal of Internal Medicine
Korean Journal of Internal Medicine MEDICINE, GENERAL & INTERNAL-
CiteScore
5.10
自引率
4.20%
发文量
129
审稿时长
20 weeks
期刊介绍: The Korean Journal of Internal Medicine is an international medical journal published in English by the Korean Association of Internal Medicine. The Journal publishes peer-reviewed original articles, reviews, and editorials on all aspects of medicine, including clinical investigations and basic research. Both human and experimental animal studies are welcome, as are new findings on the epidemiology, pathogenesis, diagnosis, and treatment of diseases. Case reports will be published only in exceptional circumstances, when they illustrate a rare occurrence of clinical importance. Letters to the editor are encouraged for specific comments on published articles and general viewpoints.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信